Blocking TGF-β or degrading ECM represents another method to promote drug infiltration into cancers, such as pancreatic cancer which are surrounded by dense ECM barrier, thus contributing to cancer therapy. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.